Richard Aldrich Net Worth

The estimated Net Worth of Richard Aldrich is at least $5.1 million dollars as of 6 June 2022. Mr. Aldrich owns over 210,526 units of Concert Pharmaceuticals Inc stock worth over $1,762,103 and over the last 13 years he sold CNCE stock worth over $3,181,163. In addition, he makes $157,592 as Independent Chairman of the Board et Co-Founder at Concert Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Aldrich CNCE stock SEC Form 4 insiders trading

Richard has made over 39 trades of the Concert Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 210,526 units of CNCE stock worth $999,999 on 6 June 2022.

The largest trade he's ever made was buying 766,667 units of Concert Pharmaceuticals Inc stock on 7 March 2013 worth over $11,500,005. On average, Richard trades about 31,655 units every 46 days since 2012. As of 6 June 2022 he still owns at least 210,526 units of Concert Pharmaceuticals Inc stock.

You can see the complete history of Mr. Aldrich stock trades at the bottom of the page.

Richard Aldrich biography

Richard H. Aldrich serves as Independent Chairman of the Board, Co-Founder of the Company. Mr. Aldrich is a co-founder of Concert and has served as a member of our Board and as Chairman of the Board since May 2006. Mr. Aldrich is a co-founder and was a Partner at Longwood Fund Management LLC, a venture capital firm, from December 2010 to December 2019. Mr. Aldrich has been an employee of Longwood Management LLC since August 2015. Mr. Aldrich founded RA Capital Management LLC, a hedge fund, in 2001 and served as a Managing Member from 2001 to 2008 and as a Co-Founding Member from 2008 to 2011. Mr. Aldrich has co-founded and helped to build several biotechnology companies including Sirtris Pharmaceuticals, Inc. (acquired by GlaxoSmithKline in 2008), Alnara Pharmaceuticals, Inc. (acquired by Eli Lilly in 2010), Verastem, Inc., OvaScience, Inc. and Flex Pharma, Inc. Mr. Aldrich was also a founding employee of Vertex Pharmaceuticals Incorporated, a pharmaceutical company, where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen Inc. Mr. Aldrich also serves on the board of directors of a number of private biotechnology companies. During the last five years, Mr. Aldrich previously served on the board of directors of PTC Therapeutics, Inc. and OvaScience, Inc. Mr. Aldrich received a B.S. in Management from Boston College and an M.B.A. from the Amos Tuck School at Dartmouth College.

What is the salary of Richard Aldrich?

As the Independent Chairman of the Board et Co-Founder of Concert Pharmaceuticals Inc, the total compensation of Richard Aldrich at Concert Pharmaceuticals Inc is $157,592. There are 7 executives at Concert Pharmaceuticals Inc getting paid more, with Roger Tung having the highest compensation of $2,772,350.

What's Richard Aldrich's mailing address?

Richard's mailing address filed with the SEC is C/O CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON, MA, 02421.

Insiders trading at Concert Pharmaceuticals Inc

Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V... et Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.

What does Concert Pharmaceuticals Inc do?

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.

Complete history of Mr. Aldrich stock trades at Concert Pharmaceuticals Inc, KalVista Pharmaceuticals Inc, PTC Therapeutics Inc et Verastem Inc

Concert Pharmaceuticals Inc executives and stock owners

Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Roger Tung,
  President, Chief Executive Officer, Co-Founder, Director
• Nancy Stuart,
  Chief Operating Officer
• Marc Becker,
  Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
• James Cassella,
  Chief Development Officer
• Dr. Roger D. Tung,
  Co-Founder, CEO, Pres & Exec. Director
• Dr. James V. Cassella,
  Chief Devel. Officer
• Jesper Hoiland,
  Independent Director
• Richard Aldrich,
  Independent Chairman of the Board, Co-Founder
• Thomas Auchincloss,
  Independent Director
• Ronald Barrett,
  Independent Director
• Peter Hutt,
  Independent Director
• Christine van Heek,
  Independent Director
• Wilfred Jaeger,
  Independent Director
• Richard H. Aldrich M.B.A., Mba,
  Co-Founder & Chairman
• Justine Koenigsberg,
  Senior Vice President, Corporate Communications and Investor Relations
• Jeffrey Munsie,
  Chief Legal Officer, Secretary
• Christine Boisclair,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Dr. Nabil Uddin Pharm.D.,
  VP of Corp. Devel.
• Jeffrey A. Munsie,
  Chief Legal Officer & Corp. Sec.
• Marc A. Becker,
  CFO & Principal Accounting Officer
• Nancy Stuart,
  Chief Operating Officer
• Wendall Wierenga,
  Director
• Wilfred Ethree Arch Managem...,
  
• Pauline Mc Gowan,
  VP, Finance
• D. Ryan Daws,
  Chief Financial Officer
• Robert Silverman,
  Senior VP, General Counsel
• Meghan Fitzgerald,
  Director
• Lynette Herscha,
  General Counsel
• Heek Christi Van,
  Director
• Ryan Lynch,
  PAO
• Partners L P/Ilbiotechnolog...,
  
• Leaf Ventures I, L.P.New Le...,
  
• Helmut Schuhsler,
  Director
• John Gordon Freund,
  Director
• Associates Gp Llcqvt Fund V...,
  
• Capital Management Llcbrook...,
  
• Ventures Fund 2004 L P Flag...,
  
• Plc Gsk,
  
• Capital Partners, L.P.Adage...,
  
• Venture Partners Qualified ...,
  
• Life Science Ventures Vi Gm...,
  
• Arch Management Iv, L.L.C.J...,
  
• Arch Management Iii Llcthre...,
  
• Arch Management Iv, L.L.C.J...,
  
• Xii Gp Llc Greylock Xii Lim...,
  
• Arch Management Iii Llcjaeg...,
  
• Jesper Hoeiland,
  Director
• Marc A. Becker,
  Chief Financial Officer